(Q80574611)

English

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study

scientific article published on 01 September 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Harold J. Burstein

1

object named as

Harold J Burstein

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

8

object named as

Eric P Winer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Rosemary Lambert-Falls

5

object named as

Rosemary Lambert-Falls

1 reference

Europe PubMed Central

PubMed publication ID

1 January 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

author name string

Aparna Keshaviah

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Ari D Baron

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Ronald D Hart

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

P Kelly Marcom

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Rebecca Gelman

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 September 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

110

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

965-972

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab/chemotherapy combinations in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel administered on a weekly basis for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22885

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22885

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614302%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80574611&oldid=2117121218"